Mentor Capital, Inc. Provides Public Market (MNTR) Funding For Cancer Immunology Leader Quantum Immunologics

Mentor Capital, Inc. (MNTR) and Quantum Immunologics, Inc. bring together $145 Million in public financing authorization with leading edge breast cancer immunotherapy now in FDA trials.

Instead of enduring mastectomies, chemotherapy and radiation,  patients receiving  Quantum's patented Oncofetal Antigen (OFA) dendritic cell therapy process, like with any dendritic cell immunotherapy process, are expected to experience only flu-like symptoms that naturally follow any immune system activation.

OFA has been found on all 500 cancers tested and is not found on healthy tissue.